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Introduction. The aim of the study was to assess the usefulness of the FC measurement in children with various types of IBD and
relation to the disease activity. Patients and Methods. 91 patients (49 boys: 53.85% and 42 girls: 46.15%, mean age: 13.38 years,
range 6–18 years) were included in the analysis. Patients were divided into the groups: B1—24 children with CD, B2—16 patients
with UC, and a group comprising 31 children with other types of colitis; the control group (K) comprised 20 healthy children.
FC was assayed by ELISA method, using Phical test (Calpro). Results. The mean faecal calprotectin concentrations were higher
in children with CD and UC as compared to healthy controls, patients with eosinophilic, lymphocytic, and nonspeciﬁc colitis. A
positive correlation was observed between FC concentrations and the disease activity (the PCDAI scale, the Truelove-Witts Scale,
and the endoscopic Rachmilewitz Index). Conclusion. It seems that the FC concentrations can be a useful, safe, and noninvasive
test in children suspected for IBD, since FC concentration is higher in children with CD and UC than in patients with other
inﬂammatory diseases.
1.Introduction
Inﬂammatory bowel disease (IBD) is a common diagnostic
and therapeutic problem, aﬀecting patients at increasingly
young ages. A standard diagnostic method includes macro-
scopic assessment of the intestinal mucosa during colono-
scopy and histopathological evaluation of the obtained bio-
psies. According to Porto criteria, the diagnosis of IBD is
based on the clinical presentation, intestinal endoscopic and
histological features, laboratory tests, and radiological exam-
ination.
There is a need for better, noninvasive methods facili-
tatingtheprocessofdiagnosing.Recently,reportsontheuse-
fulness of a noninvasive examination, that is, faecal calpro-
tectin measurement in IBD diagnosis, have been published.
Calprotectin (a neutrophil protein) is present in both blood
serum and faeces. Its concentration considerably increases
during infections and inﬂammatory conditions, including
IBD. Evaluation of faecal calprotectin (FC) seems to be a
screening test selecting patients requiring further invasive
diagnostics.
Furthermore, there have been reports on using calpro-
tectin assays in monitoring the treatment of Crohn’s disease
and ulcerative colitis in adults and children [1–4].
To our knowledge, there are no published data on the
usefulness of faecal calprotectin assays in the diagnosis
of other atypical forms of bowel inﬂammation, such as
eosinophilic, lymphocytic, or nonspeciﬁc colitis.
2.AimofStudy
The aim of the study is to assess the usefulness of faecal
calprotectin measurement in children with various types
of IBD and to evaluate FC concentration in children with
Crohn’s disease and ulcerative colitis in relation to disease
activity.
3. Patients andMethods
91 patients were included in the analysis, including 49 boys
(53.85%) and 42 girls (46.15%), ranging from 6 to 18 years2 Mediators of Inﬂammation
Table 1: Faecal calprotectin concentrations in the study subjects.
Group K Group B1 (CD) Group B2 (UC) Group B3 (EC) Group B4 (LC) Group B5 (NC)
n = 20 n = 24 n = 16 n = 7 n = 8 n = 16
Faecal calprotectin
[mg/kg]
ρεδ. 22.5 448.1 601.1 28.5 17.1 31.4
SEM 2.1 57.9 45.8 7.7 2.1 6.2
Median 14.5 436.8 616.0 24.0 12.9 26.0
Min–Max 7.1–87.5 52.5–973.4 210.5–899.5 10.3–58.7 7.5–31.4 12.5–59.6
of age (the mean age was 13.38 years). The study group
comprised 71 children with various types of IBD, who were
subsequently divided into six subgroups: B1—24 (33.8%)
children with Crohn’s disease (CD), B2—16 (22.5%) with
ulcerative colitis (UC), B3—7 (9.8%) with eosinophilic
colitis (EC), B4—8 (11.26%) with lymphocytic colitis (LC),
and B5—16 (22.5%) with nonspeciﬁc colitis (NC, coli-
tis indeterminata—CI). The control group (K) comprised
20 healthy, age- and sex-matched subjects. Patients with
IBD underwent following procedures: anamnesis, physical
examination, laboratory tests (inﬂammatory state mark-
ers, biochemical parameters of liver, pancreas, and kidney
function, sweat test, coprological tests, and immunoassays),
diagnostic imaging (abdominal ultrasound), and endoscopy
with histopathological evaluation.
Inallpatients,faecalcalprotectinwasmeasuredbymeans
of ELISA method, using Phical test (Calpro). Faeces samples
were obtained prior to administration of laxatives prepar-
ing patients for colonoscopy. Calprotectin concentrations
ranging from 0 to 50mg/kg were considered to be normal
reference values.
Data analysis was performed with Statistica software
(Microsoft). The results were evaluated by using the fol-
lowing tests: Kołmogorow-Smirnow, t-student, U Mann-
Whitney, Fisher, and Yates; the analysis of correlation was
based on the Spearman’s rank correlation coeﬃcient. A P
value of <0.05 was considered statistically signiﬁcant.
Allpatientsandtheircaregiversgaveinformedconsentto
participate in the study, which was approved by the Bioethics
Committee of the Medical University of Silesia in Katowice
(Consent no. L.dz.NN-6501-189/05/06).
4. Results
A statistically signiﬁcant increase in the mean concentrations
of faecal calprotectin was observed in the group of children
with CD and UC, as compared to the control group.
Concentrations of FC were also higher in children with
UC than in patients with CD. Faecal calprotectin concen-
trationswerewithinthenormallimitsinpatientswitheosin-
ophilic, lymphocytic, and nonspeciﬁc colitis, similarly to the
healthy subjects (Table 1, Figure 1)
In children with CD, faecal calprotectin concentra-
tions positively correlated with the disease severity assessed
according to the PCDAI scale. In patients suﬀering from
UC, faecal calprotectin also positively correlated with the
Truelove-Witts scale and the Rachmilewitz endoscopic index
(Figures 2, 3,a n d4).
A signiﬁcant increase in faecal calprotectin concentra-
tions was observed in children suﬀering from CD, with
lesions located in both small and large intestine, and in
patients presenting with inﬂammatory changes in 5 or more
sections of the intestine (Figure 5).
5. Discussion
Faecal calprotectin is a promising, noninvasive screening
method for diagnosing patients suﬀering from gastrointesti-
nal disorders, such as abdominal pain or diarrhea, which are
also typical for IBD [5–7].
So far, many authors have considered calprotectin as a
useful marker in diﬀerential diagnosis of IBD and functional
gastrointestinal disorders (e.g., irritable bowel syndrome) [8,
9].
Many authors evaluated faecal calprotectin concentra-
tions in patients with suspected inﬂammatory process of
the large intestine. Fagerberg et al. demonstrated in the
group of paediatric patients that this assay is characterised
by 95% sensitivity and 93% speciﬁcity, and high calprotectin
concentrations show strong positive correlation with the
presence of inﬂammatory lesions in the large intestine.
According to these authors, calprotectin measurement could
be a screening test preceding invasive endoscopic examina-
tions [7].
So far, only limited studies, based on very small groups
of patients, evaluated faecal calprotectin concentrations in
patients with other types of bowel inﬂammations less com-
mon than CD and UC, such as lymphocytic, eosinophilic,
and nonspeciﬁc colitis, which seem to be a considerable
clinical problem in everyday pediatric practice.
In studies conducted by Bunn et al., two children with
nonspeciﬁc colitis and 3 children with allergic colitis were
included in the analysis. In both cases, calprotectin concen-
trations were found to be within the normal ranges [10].
In our study involving 31 children: 7 with eosinophilic
colitis, 8 with lymphocytic colitis, and 16 with nonspeciﬁc
colitis, respectively, calprotectin concentrations were also
within the normal limits.
These results support the hypothesis that in the afore-
mentioned types of bowel inﬂammation, histopathological
examination does not reveal inﬁltrations of neutrophil cells,
whose cytosols contain calprotectin. Therefore, its concen-
tration in faeces is directly related to the number of neutro-
phils in the large intestine lumen [11, 12].Mediators of Inﬂammation 3
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Figure 1: Comparison of faecal calprotectin concentrations among study groups.
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Figure 2: Correlation between calprotectin concentrations and the
PCDAI score in CD children.
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Figure 3: Correlation between calprotectin concentrations and the
Truelove-Witts score in UC children.
In paediatric patients, the diagnosis of nonspeciﬁc colitis
(indeterminata colitis) remains unchanged in approximately
36%. Over time in some patients, the diagnosis may be
changed into ulcerative colitis (in approximately 33–72.5%)
or Crohn’s disease (in approximately 17–27.5%) [13].
Inourgroupof6CDpatients,previouslydiagnosedcon-
ditionsincludedsinglecasesofulcerativecolitis,lymphocytic
colitis, and nonspeciﬁc colitis, whereas eosinophilic colitis
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Figure 4: Correlation between calprotectin concentrations and the
Rachmilewitz index in children with UC.
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Figure 5: Calprotectin concentrations in relation to the location of
lesions in CD patients.4 Mediators of Inﬂammation
was found in 3 subjects. Increased calprotectin concentra-
tions may be useful when making a decision on extending
diagnostic procedures in patients with less frequent types of
bowel inﬂammation.
In our study, the mean calprotectin concentration in the
examined patients with IBD was higher than it was observed
by Bremner et al.; however, patients in remission were also
enrolled in the latter research [14].
In the presented material, a signiﬁcant correlation was
demonstrated between calprotectin activity and the disease
severity assessed by the modiﬁed PCDAI scale for CD and
the modiﬁed Truelove-Witts scale and the Rachmilewitz
endoscopic index for UC.
A similar analysis was performed by Kobelska-Dubiel
et al., demonstrating a strong positive correlation between
calprotectin concentrations and the disease severity accord-
ing to the modiﬁed Truelove-Witts scale only in UC [4].
Analyses performed in children assessed a correlation
between FC concentrations and intensity of macroscopic
and microscopic inﬂammatory lesions in the large intestine,
observed in the course of IBD. Studies carried out by
Fagerberg et al. included 39 children with IBD, in whom cal-
protectin concentrations strongly correlated with intensity
and extent of micro- and macroscopic abnormalities [15].
Norwegian researchers also conﬁrmed such a correlation
and, moreover, suggested that intensity of inﬂammatory
lesions rather than their extent inﬂuences faecal calprotectin
concentration[16].Thissuggestioncanbesupportedbydata
obtained from our study, indicating that in patients with UC
calprotectin concentration depends on disease activity and
not on the extent of lesions, in contrast to patients suﬀering
from CD. In the latter group, calprotectin concentrations
correlated with the disease activity and were signiﬁcantly
higher in children with inﬂammatory lesions present in both
small and large intestine and located in 5 or more sections
of the large intestine. These results support conclusions
from the studies on clinical expression of the disease, which
demonstrated that in children and adolescents the disease is
more severe and CD lesions are located in the small intestine
[17, 18].
So far, none of the faeces examinations appeared use-
ful in the routine diagnostics of IBD. Faecal calprotectin
measurement seems a promising test to evaluate disease
activityandatoolformonitoringIBDtreatment.Ineveryday
practice, calprotectin assay may become a screening test
preceding a decision on invasive endoscopic examination.
A disadvantage of this method is its low speciﬁcity, which
is connected with the fact that in patients with increased
calprotectin concentration many organic diseases should be
excluded.
6. Conclusion
It seems that measurement of faecal calprotectin concentra-
tion can be a useful, safe, and noninvasive test in children
suspected for IBD, since it is found to be increased in
children with CD and UC as compared to patients with
other inﬂammatory diseases (eosinophilic, lymphocytic, and
nonspeciﬁc colitis) and also in the reference to healthy
subjects.
When the faecal calprotectin concentration is increased
in children with less common types of bowel inﬂammation,
a further follow-up of such patients is recommended.
Faecal calprotectin concentration correlates positively
with the disease severity in CD and UC patients; thus, it
may be useful when choosing or modifying the appropriate
treatment regimen.
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